Mabwell Subsidiary T-mab Passes Jordan GMP Inspection for Denosumab Biosimilars

Key Takeaways

• Mabwell’s T-mab subsidiary successfully passed Jordan FDA’s GMP inspection for two denosumab biosimilar injections
• The approval covers biosimilars of Prolia® and Xgeva®, treatments for osteoporosis and bone complications in cancer patients
• This compliance certification enables potential market access in Jordan and other PIC/S member countries

---

SHANGHAI - Mabwell (688062.SH), a fully integrated biopharmaceutical company, announced that its wholly-owned subsidiary T-mab has successfully passed a Good Manufacturing Practice (GMP) inspection by the Jordan Food and Drug Administration (JFDA), receiving a “Compliance” certification.

The inspection evaluated T-mab’s manufacturing capabilities for two denosumab biosimilar injections: 9MW0311, a biosimilar to Prolia®, and 9MW0321, a biosimilar to Xgeva®. Both products target bone-related conditions, with Prolia® used primarily for osteoporosis treatment and Xgeva® for preventing bone complications in cancer patients.

Regulatory Significance

This marks Mabwell’s first successful GMP inspection by a regulatory authority from a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member country. Jordan’s participation in PIC/S means this compliance certification could facilitate regulatory recognition in other member countries, potentially accelerating global market access for Mabwell’s denosumab biosimilars.

The denosumab market represents a significant opportunity, as the original products generate billions in annual revenue globally. Biosimilar versions typically offer cost savings of 20-30% compared to reference biologics, making bone treatments more accessible to patients.

Market Impact

For Mabwell, this regulatory milestone strengthens its position in the competitive biosimilars market and validates its manufacturing quality standards. The company’s integrated approach from research to manufacturing positions it to capitalize on the growing demand for affordable biologic treatments.

The approval comes as healthcare systems worldwide seek cost-effective alternatives to expensive biologic drugs, particularly for chronic conditions requiring long-term treatment like osteoporosis.

---

Frequently Asked Questions

What does this approval mean for patients?

This GMP compliance enables Mabwell to potentially market more affordable biosimilar versions of expensive bone treatments in Jordan and potentially other countries, improving patient access to these medications.

When will these denosumab biosimilars be available?

While the GMP inspection is complete, market availability depends on additional regulatory approvals and commercial launch decisions. Timelines vary by country and regulatory pathway.

How do these biosimilars compare to original Prolia and Xgeva?

Biosimilars must demonstrate similar safety and efficacy to reference products. They typically offer the same therapeutic benefits at lower costs, usually 20-30% less than original biologics.